UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
Go back to UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting| (NYSE: UCB) | Delayed: 35.30 -0.35 (0.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.65 | 52 Week High | $ | |||
| Open | $35.89 | 52 Week Low | $ | |||
| Day High | $35.98 | P/E | N/A | |||
| Day Low | $35.30 | EPS | $ | |||
| Volume | 646,906 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 144.63 -1.7 (1.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.33 | 52 Week High | $46.25 | |||
| Open | $145.79 | 52 Week Low | $32.74 | |||
| Day High | $145.98 | P/E | N/A | |||
| Day Low | $144.53 | EPS | $0.00 | |||
| Volume | 25,507 | |||||
